Alibaba Health Information Technology Limited

HKG-0241
Hong Kong Stock Exchange
Healthcare Pharmaceutical Retailers
Global Rank
#3191
Country Rank
#530
Market Cap
6.47 B
Price
0.4
Change (%)
3.29%
Volume
65.97 M

Alibaba Health Information Technology Limited's latest marketcap:

6.47 B

As of 09/04/2026, Alibaba Health Information Technology Limited's market capitalization has reached $6.47 B. According to our data, Alibaba Health Information Technology Limited is the 3191th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 6.47 B
Revenue (ttm) 4.97 B
Net Income (ttm) 280.68 M
Shares Out 16.16 B
EPS (ttm) 0.02
Forward PE 20.92
Ex-Dividend Date 08/12/2026
Earnings Date 09/10/2026
Market Cap Chart
Data Updated: 09/04/2026

Alibaba Health Information Technology Limited's yearly market capitalization.

Alibaba Health Information Technology Limited has seen its market value grow from HK$41.6 B to HK$50.76 B since 2014, representing a total increase of 22.02% and an annual compound growth rate (CAGR) of 1.72%.
Date Market Cap(HK$) Market Cap(USD) Change (%) Global Rank
09/04/2026 HK$50.76 B $6.47 B -39.5% 3191
12/31/2025 HK$81.63 B $10.48 B 52.89% 1923
12/31/2024 HK$53.39 B $6.87 B -6.88% 2345
12/29/2023 HK$57.34 B $7.34 B -36.18% 2102
12/30/2022 HK$89.84 B $11.5 B 1.14% 1350
12/31/2021 HK$88.83 B $11.39 B -71.15% 1640
12/31/2020 HK$307.9 B $39.7 B 184.67% 428
12/31/2019 HK$108.16 B $13.88 B 45.98% 991
12/31/2018 HK$74.09 B $9.46 B 100.04% 1170
12/29/2017 HK$37.04 B $4.74 B 16.06% 2449

Company Profile

About Alibaba Health Information Technology Limited

Alibaba Health Information Technology Limited is an investment holding company specializing in pharmaceutical and healthcare services across Mainland China and Hong Kong. The company operates through multiple business segments, including direct pharmaceutical sales, e-commerce platforms, and digital healthcare solutions.

Core Business Offerings

  • Pharmaceutical Sales: Provides prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, health food, and skincare products.
  • Healthcare Services: Offers medical checkups, nucleic acid testing, consultations, appointment bookings, vaccinations, dental care, mental health services, optometry, and traditional Chinese medicine.
  • Distribution Channels: Serves B2C and B2B customers through offline pharmacies and online platforms like Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark.

Additional Services

  • Digital tracking and healthcare-related internet services.
  • Operation of internet hospitals and Doctor U, a platform for doctor-patient education.
  • Software technical services and asset management.

Company Background

Formerly known as CITIC 21CN Company Limited, the company rebranded as Alibaba Health Information Technology Limited in September 2014. Founded in 1998, it is headquartered in Causeway Bay, Hong Kong.

Frequently Asked Questions

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.